- Home
- KRYS
KRYS
Krystal Biotech Inc.
as 05-30-2025 12:38pm EST
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 3.7B | IPO Year: | 2017 |
| Target Price: | $211.13 | AVG Volume (30 days): | 425.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.16 | EPS Growth: | 109.01 |
| 52 Week Low/High: | $122.80 - $219.34 | Next Earning Date: | 05-06-2025 |
| Revenue: | $333,448,000 | Revenue Growth: | 247.53% |
| Revenue Growth (this year): | 48.66% | Revenue Growth (next year): | 49.81% |
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | KRYS | President and CEO | Mar 13 '25 | Sell | $177.74 | 50,000 | $8,889,524.59 | 1,463,711 | |
| Krishnan Suma | KRYS | President, R&D | Mar 13 '25 | Sell | $177.74 | 50,000 | $8,889,524.59 | 1,487,072 |
Latest Krystal Biotech Inc. News
KRYS Breaking Stock News: Dive into KRYS Ticker-Specific Updates for Smart Investing
Argus Research
10 days ago
KRYS: Lowering target price to $145.00
Argus Research
17 days ago
KRYS: Lowering target price to $148.00
Simply Wall St.
17 days ago
Krystal Biotech's (NASDAQ:KRYS) Solid Earnings Have Been Accounted For Conservatively
TipRanks
20 days ago
Biotech Alert: Searches spiking for these stocks today
Insider Monkey
21 days ago
Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain
GlobeNewswire
23 days ago
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
Simply Wall St.
23 days ago
Krystal Biotech First Quarter 2025 Earnings: Misses Expectations
GuruFocus.com
23 days ago
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...
Compare KRYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.